Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 23.640 (Stand 01. Juli 2025)
Amgevita® (Adalimumab)257
Benepali® (Etanercept)1288
Cimzia® (Certolizumab)1056
Enbrel® (Etanercept)2878
Erelzi® (Etanercept)615
Flixabi® (Infliximab)10
Hukyndra® (Adalimumab)17
Hulio® (Adalimumab)301
Humira® (Adalimumab)2912
Hyrimoz® (Adalimumab)278
Idacio® (Adalimumab)72
Imraldi® (Adalimumab)247
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)181
Kevzara® (Sarilumab)235
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)103
Olumiant® (Baricitinib)561
Orencia® (Abatacept)998
Remicade® (Infliximab)762
Remsima® (Infliximab)27
Rinvoq® (Upadacitinib)341
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1382
Ruxience® (Rituximab)1
Simponi® (Golimumab)479
Truxima® (Rituximab)8
Tyenne® (Tocilizumab)68
Xeljanz® (Tofacitinib)403
Yuflyma® (Adalimumab)65
Zessly® (Infliximab)2
Kontrollen6509